Skip to main content

Webinar with winners of the EACR & Novosanis research grant: Part 2

Novosanis is excited to host an upcoming webinar with winners of the EACR & Novosanis research grant, which will highlight cancer biomarker detection in urine. The webinar will have two presentations, by speakers Dr Barbara Guinn from University of Hull winner of the Grant, and Koen Beyers, Co-Founder of Novosanis.

Don't miss out! Register here today.

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.